eXoZymes (EXOZ)
NASDAQ:EXOZ
Want to see EXOZ full AI Analyst Report?
EXOZ Stock Chart & Stats
$11.49
--
Market closed
$11.49
--
Day’s Range― - ―
52-Week Range$7.08 - $18.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.40K
Market Cap
N/A
Enterprise Value$82.14M
Total Cash (Recent Filing)$1.44M
Total Debt (Recent Filing)$1.16M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding8,478,992
10 Day Avg. Volume1,191
30 Day Avg. Volume2,398
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)26.89
Price to Sales (P/S)0.00
P/FCF Ratio-13.69
Enterprise Value/Market Cap10.00T>
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-22.54K
Enterprise Value/Ebitda-8.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital AccessActive engagement with underwriters and a prepared investor presentation signal formal steps to access public capital. Over the medium term this can materially extend runway, fund R&D and development milestones, and reduce immediate liquidity strain if executed successfully.
Moderate LeverageMeasured debt relative to equity provides financial flexibility for an early-stage biotech. Moderate leverage lowers insolvency risk versus highly levered peers and leaves capacity to raise targeted debt or structure financing without immediately crowding out operational investment.
Focused Investor MessagingRefreshing and circulating materials for the NCTx business indicates clearer strategic focus and improved investor communication. Over months this supports more efficient capital allocation, targeted partner discussions, and better alignment of management priorities with development goals.
Bears Say
Pre-revenue, Widening LossesThe company has no product revenue and materially larger operating losses over recent years. Persistent negative earnings drain equity and limit reinvestment capacity, creating a structural need for external funding until commercialization or licensing yields sustainable revenues.
Heavy Cash BurnConsistently negative operating and free cash flow signals ongoing financing dependence. Sustained cash burn constrains strategic optionality, increases execution risk on R&D programs, and makes the business vulnerable to capital-market volatility over the coming quarters.
Dilution / Financing OverhangA contemplated securities offering addresses funding needs but introduces dilution and a financing overhang. Structurally, repeated or large equity raises can erode shareholder value and complicate long-term incentive alignment if operating losses persist and milestones are delayed.
eXoZymes News
EXOZ FAQ
What was eXoZymes’s price range in the past 12 months?
eXoZymes lowest stock price was $7.08 and its highest was $18.40 in the past 12 months.
What is eXoZymes’s market cap?
Currently, no data Available
When is eXoZymes’s upcoming earnings report date?
eXoZymes’s upcoming earnings report date is Aug 18, 2026 which is in 80 days.
How were eXoZymes’s earnings last quarter?
Currently, no data Available
Is eXoZymes overvalued?
According to Wall Street analysts eXoZymes’s price is currently Overvalued.
Does eXoZymes pay dividends?
eXoZymes does not currently pay dividends.
What is eXoZymes’s EPS estimate?
eXoZymes’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does eXoZymes have?
eXoZymes has 8,478,992 shares outstanding.
What happened to eXoZymes’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of eXoZymes?
Currently, no hedge funds are holding shares in EXOZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
eXoZymes
eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
EXOZ Earnings Call
Q4 2026
0:00 / 0:00
Technical Analysis
Ownership Overview
17.19% Insiders
0.49% Mutual Funds
― Other Institutional Investors
81.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---